<DOC>
	<DOCNO>NCT02076451</DOCNO>
	<brief_summary>This Phase 1 , open-label study DS-8273a ass safety tolerability , identify Maximum Tolerated Dose and/or Maximum Administered Dose , ass property subject advance solid tumor lymphomas . Up 5 US site plan participation Part 1 ( Dose Escalation ) Part 2 ( Dose Expansion ) subject solid tumor lymphomas .</brief_summary>
	<brief_title>Open-label Study DS-8273a Assess Its Safety Tolerability , Assess Its Pharmacokinetic Pharmacodynamic Properties Subjects With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Has histologically cytologically document advanced solid tumor lymphoma relapse refractory standard treatment , standard treatment available . Man woman &gt; = 18 year old . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Has adequate bone marrow function , define : Platelet count &gt; = 100 X 10*9/L Hemoglobin level &gt; = 9.0 g/dL Absolute neutrophil count &gt; = 1.5 x 10*9/L Has adequate renal function , define : Creatinine clearance &gt; = 60 mL/minute , calculate use modify Cockroft Gault equation , ( [ { 140 age year } × { actual weight kg } ] divide [ { 72 × serum creatinine mg/dL } multiply 0.85 female ] ) , OR creatinine &lt; = 1.5 X upper limit normal ( ULN ) Has adequate hepatic function , define : AST/ALT &lt; = 3 X ULN ( liver metastasis present , &lt; = 5 X ULN ) Bilirubin &lt; = 1.5 X ULN Has adequate blood clot function , define : International normalize ratio activate partial thromboplastin time &lt; = 1.5 X ULN Subject able provide write informed consent comply protocol visit procedure . Subject ( male female ) childbearing/ reproductive potential must agree use double barrier contraceptive measure avoid intercourse study 90 day last dose study drug . Subject must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date Institutional Review Boardapproved Informed Consent Form ( include Health Insurance Portability Accountability Act authorization , applicable ) performance study specific procedure test . Is willing provide preexist diagnostic resect tumor sample , paraffinembedded section . Providing fresh tumor biopsy sample optional . Following treatmentfree period prior enrollment study : ) Surgery : 4 week major surgery ( e.g. , laparotomy thoracotomy ) ; 2 week less extensive surgery ( e.g. , colostomy ) ii ) Radiation : 4 week ( 2 week palliative irradiation bone metastases [ except pelvic irradiation ] , brain metastasis ) iii ) Chemotherapy ( include systemic treatment anticancer therapy retinoid therapy ) : 3 week ( 6 week nitrosourea antineoplastic agent mitomycin C ) iv ) Antibodybased therapy : 4 week v ) Small molecule target agent : If myelosuppression expect , 2 week 5 halflives , whichever longer ; otherwise , 3 week vi ) Hormonal treatment : 3 week . Previous concurrent use hormone replacement therapy , use gonadotropinreleasing hormone modulators prostate cancer , use somatostatin analog neuroendocrine tumor permit therapy change within 8 week study drug treatment . vii ) Pleurodesis : 2 week Has history primary central nervous system malignancy . Has uncontrolled infection require IV antibiotic , antiviral , antifungal , know human immunodeficiency virus infection , active hepatitis B C infection . Has receive allogeneic bone marrow allogeneic stem cell transplant . Has concomitant medical condition would increase risk toxicity , opinion Investigator Sponsor . Has clinically active brain metastasis , define untreated symptomatic , require therapy steroid anticonvulsant control associate symptom . Subjects treat brain metastasis longer symptomatic require treatment steroid may include study recover acute toxic effect radiotherapy . A minimum 4 week must elapse end whole brain radiotherapy study enrollment ( 2 week stereotactic radiotherapy ) . Has unresolved toxicity prior anticancer therapy , define toxicity ( chemotherapy , hormonal treatment , radiation , and/or surgery ) yet resolve NCICTCAE , v4 , Grade &lt; = 1 baseline ; alopecia , skin toxicity ( Grade 1 ) , accord NCICTCAE , v4 . Subjects chronic Grade 2 toxicity may eligible per discretion Investigator Sponsor ( e.g. , Grade 2 chemotherapyinduced peripheral neuropathy ) . Had autologous transplant within 3 month start study drug treatment . Participated therapeutic clinical study within 3 week ( 2 week 5 halflives , whichever longer , smallmolecule target agent ) study drug treatment , current participation therapeutic investigational procedure . Prolongation correct QT interval Fridericia 's method ( QTcF ) rest , mean QTcF interval &gt; 450 m male &gt; 470 m female base triplicate electrocardiogram ( ECG ) . Pregnant breastfeeding . Substance abuse medical , psychological , social condition , opinion Investigator , may interfere subject 's participation clinical study evaluation clinical study result . Prior treatment human DR5 agonist . Life expectancy &lt; 3 month opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>